Financial Data and Key Metrics Changes - Revenue for the second quarter was $116,000, compared to $0 in the same period last year, primarily from cost reimbursements under a collaboration agreement with Boehringer Ingelheim [6] - Total operating expenses increased to $7.4 million from $2.6 million in the prior year, driven by higher investments in obesity development programs and increased compensation costs [6][7] - Net loss for the quarter was $7.3 million, or $2.86 per share, compared to a net loss of $2.4 million, or $5.92 per share in the comparable period last year [8] - Cash and cash equivalents as of December 31, 2025, were $14.5 million, up from $1.3 million at September 30, 2025 [9] Business Line Data and Key Metrics Changes - The company is advancing its melanocortin-4 receptor-based obesity pipeline, focusing on rare syndromic and genetic obesity disorders [10] - The lead oral small molecule MC4R agonist, PL7737, is progressing through IND-enabling toxicology studies, with an IND submission planned for the first half of 2026 [11] - Next-generation selective melanocortin-4 receptor peptide agonists are also being developed, with an IND submission planned for the second half of 2026 [11] Market Data and Key Metrics Changes - The company regained compliance with NYSE American listing standards, and its common stock resumed trading under the symbol PTN [5][13] - The focus remains on rare neuroendocrine obesity disorders, including hypothalamic obesity and Prader-Willi syndrome, which represent significant unmet medical needs [10][12] Company Strategy and Development Direction - The company aims to deliver differentiated product profiles with a focus on enhancing patient tolerability and minimizing off-target effects [11] - A sub-licensing transaction for PL9643 provided approximately $3.8 million in upfront consideration, allowing the company to sharpen its focus on core obesity programs [12][13] - The company is positioned to pursue substantial long-term value creation through multiple partnerships and near-term milestones [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products, particularly regarding tolerability and safety profiles compared to existing treatments [17][34] - The company anticipates moving forward into phase II studies for both oral small molecules and long-acting peptides targeting hypothalamic obesity and Prader-Willi syndrome patients by mid-2027 [43] Other Important Information - The company completed an $18.2 million public offering, which significantly strengthened its balance sheet and provided capital for advancing its obesity pipeline [5][10] - The company expects its cash runway to extend beyond the quarter ending March 31, 2027 [9] Q&A Session Summary Question: What preclinical or translational signals give confidence in differentiation for PL7737? - Management highlighted the design of the compound to be more selective for the melanocortin-4 receptor, which should reduce hyperpigmentation and control GI side effects [17] Question: How will patient selection and endpoints be approached in the phase one study? - The focus will be on safety and confirming oral absorption, with weight reduction and control of hyperphagia as key parameters in the multiple-ascending dose study [19][20] Question: Is there an increased emphasis on Prader-Willi syndrome? - Management confirmed that while Prader-Willi has always been in the background, they are focusing on indications with substantial patient populations [21][22] Question: How will the oral small molecule and weekly injection be positioned? - Both products are seen as complementary, with each suited for different patient populations [24][25] Question: What is the anticipated cash flow and resource allocation for PWS studies? - Management indicated sufficient cash to move forward with both oral and peptide studies, with plans to initiate studies in PWS patients by mid-2027 [43] Question: How will GLP-1 therapies be integrated into product development? - Management anticipates that combination therapies will be necessary for optimizing treatment, particularly for patients with severe hyperphagia [48]

Financial Data and Key Metrics Changes - Revenue for the second quarter was $116,000, compared to $0 in the same period last year, primarily from cost reimbursements under a collaboration agreement with Boehringer Ingelheim [6] - Total operating expenses increased to $7.4 million from $2.6 million in the prior year, driven by higher investments in obesity development programs and increased compensation costs [6][7] - Net loss for the quarter was $7.3 million, or $2.86 per share, compared to a net loss of $2.4 million, or $5.92 per share in the comparable period last year [8] - Cash and cash equivalents as of December 31, 2025, were $14.5 million, up from $1.3 million at September 30, 2025 [9] Business Line Data and Key Metrics Changes - The company is advancing its melanocortin-4 receptor-based obesity pipeline, focusing on rare syndromic and genetic obesity disorders [10] - The lead oral small molecule MC4R agonist, PL7737, is progressing through IND-enabling toxicology studies, with an IND submission planned for the first half of 2026 [11] - The next generation selective melanocortin-4 receptor peptide agonists are also being developed, with an IND submission planned for the second half of 2026 [11] Market Data and Key Metrics Changes - The company has regained compliance with NYSE American listing standards, and its common stock resumed trading under the symbol PTN [5][13] - The focus remains on rare neuroendocrine obesity disorders, including hypothalamic obesity and Prader-Willi syndrome, which represent significant unmet medical needs [10][12] Company Strategy and Development Direction - The company aims to deliver differentiated product profiles with a focus on enhancing patient tolerability and minimizing off-target effects [11] - A strategic shift was made by sub-licensing the dry eye disease clinical candidate, PL9643, to focus more on core obesity programs [12][13] - The company is positioned to pursue long-term value creation through multiple partnerships and a focused pipeline [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products, particularly regarding tolerability and safety profiles compared to current treatments [17][34] - The company anticipates moving into phase II studies for Prader-Willi syndrome and hypothalamic obesity patients by mid-2027 [43] - Management highlighted the importance of combination therapies with GLP-1 based treatments as the market evolves [48] Other Important Information - The company completed a public offering of $18.2 million, strengthening its balance sheet and providing capital for advancing obesity programs [5][10] - The company expects its cash runway to extend beyond March 31, 2027, based on current operating plans [9] Q&A Session Summary Question: What preclinical signals give confidence in differentiation for PL7737? - Management highlighted the design of the compound to be more selective for the melanocortin-4 receptor, which should reduce hyperpigmentation and control GI side effects [17] Question: How will patient selection and endpoints be defined for phase one studies? - The focus will be on safety and confirming oral absorption, with weight reduction and control of hyperphagia as key metrics in the multiple-ascending dose study [19][20] Question: Is there an increased emphasis on Prader-Willi syndrome? - Management confirmed that while it has always been in the background, there is a focus on larger indications like hypothalamic obesity and Prader-Willi syndrome due to the number of patients [22] Question: How will the oral small molecule and weekly injection be positioned? - Both products are seen as complementary, with each suited for different patient populations [24][25] Question: What is the anticipated cash flow for the next quarters? - Management indicated that there were one-time extraordinary expenses in the previous quarter, and they expect operating expenses to decrease in the upcoming quarters [27][28]

Financial Data and Key Metrics Changes - Revenue for Q2 2026 was $116,000, compared to $0 in the same period last year, attributed to cost reimbursements from a collaboration with Boehringer Ingelheim [7] - Total operating expenses increased to $7.4 million from $2.6 million in the prior year, primarily due to higher investments in obesity development programs and increased compensation costs [7] - Net loss for the quarter was $7.3 million, or $2.86 per share, compared to a net loss of $2.4 million, or $5.92 per share in the prior year [8] - Cash and cash equivalents as of December 31, 2025, were $14.5 million, up from $1.3 million at September 30, 2025 [10] Business Line Data and Key Metrics Changes - The company is advancing its melanocortin-4 receptor-based obesity pipeline, focusing on rare syndromic and genetic obesity disorders [11] - The lead oral small molecule MC4R agonist, PL7737, is progressing through IND-enabling toxicology studies, with plans to submit an IND in the first half of 2026 [12] - A next-generation selective melanocortin-4 receptor peptide agonist is also in development, with an IND submission planned for the second half of 2026 [12] Market Data and Key Metrics Changes - The company regained compliance with NYSE American listing standards, allowing its common stock to resume trading under the symbol PTN [6][14] - The focus remains on rare neuroendocrine obesity disorders, including hypothalamic obesity and Prader-Willi syndrome, which represent significant unmet medical needs [12] Company Strategy and Development Direction - The company aims to deliver differentiated product profiles with a focus on enhancing patient tolerability and minimizing side effects [12] - A strategic sub-licensing of PL9643 for dry eye disease has allowed the company to sharpen its focus on core obesity programs while retaining potential future financial participation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial position and pipeline, indicating that the successful public offering has provided the necessary capital to advance obesity programs [11][14] - The company anticipates a cash runway extending beyond March 31, 2027, based on current operating plans [10] Other Important Information - The company received approximately $3.8 million in upfront consideration from the sublicensing transaction, which will be recognized as licensed revenue in the quarter ending March 31, 2026 [10] Q&A Session Summary Question: What preclinical or translational signals give confidence in differentiation for PL7737? - The compound is designed to be more selective for the melanocortin-4 receptor, which should reduce hyperpigmentation and control GI side effects through its administration [17][18] Question: How will patient selection and endpoints be approached in the phase one study? - The phase one studies will primarily focus on safety, with the multiple-ascending dose study looking for reductions in body weight and control of hyperphagia [19][20] Question: Is there an increased emphasis on Prader-Willi syndrome? - Prader-Willi syndrome has always been in the background, but the company is focusing on larger indications with substantial patient populations [22] Question: How will the oral small molecule and weekly injection be positioned? - Both products are seen as complementary, with each suited for different patient populations [24][26] Question: What is the anticipated impact of GLP-1 therapies on product development? - The company is exploring combination therapies with GLP-1s to optimize treatment for patients with severe hyperphagia [49]

Core Viewpoint - Palatin Technologies, Inc. reported its financial results for the second quarter of fiscal year 2026, highlighting advancements in its MC4R-based obesity programs and a strengthened financial position through a successful public offering [1][2]. Financial Results - For the second quarter ended December 31, 2025, Palatin recognized $116,036 in collaboration and license revenue, a significant increase from $0 in the same quarter last year, attributed to the agreement with Boehringer Ingelheim [2]. - Total operating expenses were $7.4 million, up from $2.6 million in the comparable quarter last year, primarily due to increased costs in MCR obesity development programs and higher compensation costs [2]. - The net loss for the quarter was $7.3 million, or $(2.86) per share, compared to a net loss of $2.4 million, or $(5.92) per share, in the same quarter last year [2][4]. - As of December 31, 2025, cash and cash equivalents were $14.5 million, a significant increase from $1.3 million at the end of September 2025 [2][4]. Corporate Update - The company completed an $18.2 million public offering on November 12, 2025, which included the full exercise of the over-allotment option, allowing it to regain compliance with NYSE American listing standards [2]. - Palatin's obesity program focuses on developing differentiated MC4R agonists aimed at enhancing patient tolerability and addressing significant unmet medical needs in conditions like hypothalamic obesity and Prader-Willi syndrome [1][3]. - The company has initiated IND-enabling toxicology studies for its oral small-molecule MC4R agonist PL7737, with plans for clinical trial initiation in the first half of 2026 [1][3]. Obesity Program Update - PL7737 is expected to enter clinical evaluation in the first half of 2026, demonstrating meaningful weight loss and oral bioavailability in preclinical models [1]. - Next-generation selective peptide MC4R agonists are designed for once-weekly subcutaneous dosing, with clinical trials anticipated to start in the second half of 2026 [1]. - The obesity program aims to address rare and broader obesity indications, particularly focusing on neuroendocrine disorders [1][3]. Out-Licensing Programs Update - Collaboration with Boehringer Ingelheim for retinal diseases could yield up to €12.5 million ($14.5 million) in research milestones and up to €260 million ($307 million) in development and commercial milestones [1]. - The sublicensing agreement for PL9643, an MC1R agonist for dry eye disease, provided $3.8 million in upfront consideration, enhancing the company's financial position [1][2]. - Active out-licensing discussions are ongoing for PL8177 (ulcerative colitis) and diabetic nephropathy programs, reflecting interest from potential partners [1].

Financial Data and Key Metrics Changes - For Q1 2026, Palatin reported approximately $8.8 million in collaboration license revenue, a significant increase from zero in the same quarter last year, primarily due to the agreement with Boehringer Ingelheim [9] - Total operating expenses decreased to $4.2 million from $7.8 million in the comparable quarter last year, mainly due to reduced spending on development programs [10] - The company reported a net income of $4.7 million for the quarter, compared to a net loss of $7.8 million in the same quarter last year, driven by the revenue from the BI agreement and lower operating expenses [11] - Cash and cash equivalents as of September 30, 2025, were $1.3 million, down from $2.6 million as of June 30, 2025, but this does not include a $6.5 million milestone payment received in October 2025 [11] Business Line Data and Key Metrics Changes - The increase in collaboration license revenue is attributed entirely to the Boehringer Ingelheim agreement, which included an upfront payment and milestone achievements [9] - The company is focusing on the development of melanocortin-4 receptor agents for obesity treatment, with a proprietary portfolio that includes both orally active small molecules and long-acting peptides [13][15] Market Data and Key Metrics Changes - The collaboration with Boehringer Ingelheim validates the potential of targeting the melanocortin system, with expectations for additional development and regulatory milestones [16] - The company anticipates a multi-billion-dollar market for obesity treatments, indicating a competitive landscape with room for multiple players [25] Company Strategy and Development Direction - Palatin's R&D efforts will concentrate on melanocortin-4 receptor agents for syndromic and genetic obesity, aiming to improve dosing profiles and reduce side effects compared to current treatments [13][15] - The company plans to initiate IND-enabling studies for its compounds in the first half of 2026, with first-in-human studies expected in the second half of 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made with the Boehringer Ingelheim collaboration and the successful public offering, which has improved the company's financial standing and compliance with NYSE American listing standards [8][12] - The company expects a cash runway beyond December 31, 2026, indicating a stable financial outlook for ongoing operations [11] Other Important Information - The company executed an $18.2 million equity offering, which has provided significant non-dilutive capital and allowed for the resumption of trading on the NYSE American under the PTN ticker symbol [17] - The company is also exploring licensing opportunities for other melanocortin receptor system programs, including candidates for dry eye disease and ulcerative colitis [16] Q&A Session Summary Question: Can you highlight the ideal target profile for PL7737 and the long-acting peptides? - Management emphasized the importance of minimizing activity at the melanocortin-1 receptor and achieving a flat pharmacokinetic curve for effective obesity treatment [19][20] Question: How do these next-generation compounds address hyperpigmentation side effects? - The company has developed selective agonists that significantly reduce activity at the melanocortin-1 receptor, potentially eliminating skin darkening side effects [23] Question: How does the company position itself against competitors in the obesity treatment market? - Management believes that the quality of their compounds, which reduce potential side effects and maximize efficacy, will allow them to compete effectively in a multi-billion-dollar market [25] Question: When might we see the next collaboration from other pipeline compounds? - Management anticipates near-term resource development milestones of approximately $15 million within the next 12 months following the successful collaboration with Boehringer Ingelheim [27]

Core Insights - Palatin Technologies, Inc. is making significant advancements in its obesity pipeline, particularly with the oral small molecule PL7737, which is expected to enter clinical studies in the first half of 2026 [2][8] - The company has strengthened its financial position through an $18.2 million public offering and has resumed trading on the NYSE American [5][10] - Collaboration with Boehringer Ingelheim is progressing, with milestones achieved and additional potential payments outlined [7][8] Obesity Program Update - PL7737 has shown robust weight loss and safety in preclinical models, with IND-enabling toxicology studies ongoing [8] - The U.S. FDA has granted Orphan Drug Designation for PL7737 for treating leptin receptor deficiency-related obesity [8] - Next-generation selective peptide MC4R agonists are planned for mid-2026 clinical trials [8] Financial Results - For the fiscal first quarter ended September 30, 2025, Palatin reported collaboration and license revenue of $8,847,550, a significant increase from $0 in the same quarter last year [11] - Total operating expenses decreased to $4.2 million from $7.8 million year-over-year, primarily due to reduced spending on MCR development programs [12] - The company reported a net income of $4.7 million for the quarter, compared to a net loss of $7.8 million in the prior year [15] Cash Position - As of September 30, 2025, Palatin had cash and cash equivalents of $1.3 million, down from $2.6 million as of June 30, 2025 [16] - The company expects a cash runway beyond December 31, 2026, factoring in upcoming milestone payments and proceeds from the recent public offering [17] Corporate Developments - The company regained compliance with NYSE American listing standards following the public offering, allowing its common stock to resume trading under the symbol "PTN" [10] - A teleconference and webcast are scheduled for November 13, 2025, to discuss operational results and corporate updates [18]

Financial Data and Key Metrics Changes - For the quarter ended March 31, 2025, Palatin reported total operating expenses of $4.8 million, a decrease from $9.2 million in the same quarter last year, primarily due to reduced spending on MCR programs [5][6] - The net loss for the quarter was $4.8 million, down from $8.4 million for the same period in 2024, driven by decreased operating expenses [6] - Cash and cash equivalents as of March 31, 2025, were $2.5 million, down from $9.5 million as of June 30, 2024 [7] Business Line Data and Key Metrics Changes - Palatin did not record any product sales for the quarter due to the completion of the sale of Vyleesi's worldwide rights for up to $171 million in December 2023 [5] - Positive top-line data was reported for the Phase II study of the melanocortin-four receptor obesity program, showing a weight reduction of 4.4% for the combined treatment compared to 1.6% for the placebo [10] Market Data and Key Metrics Changes - The FDA granted orphan drug status to PL7737 for treating patients with obesity due to leptin receptor deficiency, indicating potential market opportunities [11] - The obesity treatment market is expected to exceed $100 billion annually, highlighting significant growth potential for melanocortin-four receptor agonists [15][16] Company Strategy and Development Direction - The company is focusing on research and development of melanocortin-four receptor obesity assets, believing it to be in the early stages of a multi-year innovation cycle [15] - Palatin aims to eliminate MCR-one activity in its next-generation compounds to reduce skin darkening side effects, enhancing patient compliance [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operating results, describing the quarter as phenomenal despite challenges with the NYSE delisting [27] - The company is actively engaging with multiple funding sources to address future operating cash requirements [7] Other Important Information - Trading of Palatin's common stock was suspended on the NYSE American due to low selling prices, and the stock began trading on the OTC Pink market [4] Q&A Session Summary Question: Will a higher dose of remelanotide increase weight loss? - Management indicated that higher doses of bremelanotide could yield comparable weight loss to single-agent treatments like Wegovy [18] Question: Will weight maintenance become a focus in future generations of treatments? - Management confirmed that newer compounds will be evaluated for long-term weight maintenance, addressing rebound weight regain [20][21] Question: What benefits will separate the next generation of MC4Rs from the first generation? - Management highlighted improvements such as reduced pigmentation side effects and more patient-friendly dosing schedules for the next-generation compounds [22][24]

Financial Data and Key Metrics Changes - For the fiscal third quarter ended March 31, 2025, Palatin reported total operating expenses of $4.8 million, a decrease from $9.2 million in the same quarter last year, primarily due to reduced spending on MCR programs [6][7] - The net loss for the quarter was $4.8 million, down from $8.4 million for the same period in 2024, driven by decreased operating expenses [7] - Cash and cash equivalents as of March 31, 2025, were $2.5 million, down from $9.5 million as of June 30, 2024 [8] Business Line Data and Key Metrics Changes - Palatin did not record any product sales for the quarter due to the completion of the sale of Vyleesi's worldwide rights for up to $171 million in December 2023 [6] - Positive top-line data was reported for the Phase II study of the melanocortin-four receptor obesity program, showing a weight reduction of 4.4% for the combined treatment compared to 1.6% for the placebo [10] - The Phase II study of PL-8177 for ulcerative colitis showed clinical remission in 33% of treated patients versus 0% for placebo, indicating significant efficacy [12] Market Data and Key Metrics Changes - The company is actively engaged in business development discussions for its obesity and ulcerative colitis programs, which aligns with its strategy to out-license these programs [12][13] - The pharmacological treatment of obesity is expected to enter a multi-year cycle of innovation, with a market value projected to exceed $100 billion annually [15] Company Strategy and Development Direction - The company is focusing its R&D efforts on melanocortin-four receptor obesity assets, believing they will play a critical role in future obesity treatment [15] - The next-generation melanocortin-four receptor compounds aim to eliminate skin darkening side effects and improve dosing convenience, with a goal of once-weekly or once-daily administration [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the NYSE's decision to suspend trading and delist the company's stock, indicating they are assessing all available options [5] - The management believes the recent positive clinical data will enhance business development opportunities and is optimistic about future partnerships [12][14] Other Important Information - The company is actively seeking multiple funding sources to address future operating cash requirements [8] - The FDA granted orphan drug status to PL-7737 for treating obesity due to leptin receptor deficiency, which is expected to support its development [11] Q&A Session Summary Question: Will a higher dose of remelanotide increase weight loss? - Management indicated that higher doses of bremelanotide have been studied and can achieve weight loss comparable to single-agent treatments like Wegovy [17] Question: Will weight maintenance become a focus in future generations of treatments? - Management confirmed that newer compounds will be evaluated for long-term weight maintenance, addressing the rebound weight regain issue [19][20] Question: What benefits will the next generation of MC4Rs have over the first generation? - Management highlighted that the next generation aims to eliminate pigmentation issues and improve dosing frequency, making them more competitive in the market [21][22]

Core Insights - Palatin Technologies has announced updated results from the Phase 3 MELODY-1 clinical trial for PL9643, indicating its potential as a first-in-class therapy for dry eye disease (DED) with full symptom resolution [2][3][4] Clinical Trial Results - The responder analysis showed statistically significant complete symptom resolution across multiple endpoints, with six out of thirteen symptom endpoints demonstrating a higher percentage of patients achieving resolution with PL9643 compared to placebo (p<0.05) [6][7] - The Symptom Composite Score for PL9643-treated patients indicated significant symptom resolution by week 2, with continued improvement through week 12, while the placebo group showed minimal improvement that plateaued early [6][7] - The Phase 3 MELODY-1 trial involved 575 patients and met statistical significance for the co-primary symptom endpoint of pain (P<0.025) and seven secondary symptom endpoints (P<0.05) [10] Regulatory and Market Context - The findings align with FDA approval guidance for dry eye drug development, which supports the use of responder analyses to demonstrate symptom improvement [9] - The dry eye disease market is projected to grow from an estimated $6.11 billion in 2024 to $7.46 billion by 2029, at a CAGR of 4.09% [11] Company Strategy and Future Plans - Palatin Technologies aims to finalize collaboration deals in the second half of the year and plans to begin patient enrollment for the remaining Phase 3 studies (MELODY-2 and MELODY-3) in the same timeframe [9][10] - The company focuses on developing first-in-class medicines targeting significant unmet medical needs, particularly in the area of dry eye disease [14]

S-1 1 ptn_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. 333-__________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Palatin Technologies, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 95-4078884 (I.R.S. Employer Identifi ...